Comparative Pharmacology
Head-to-head clinical analysis: LARIN FE 1 20 versus MODICON 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN FE 1 20 versus MODICON 21.
LARIN FE 1/20 vs MODICON 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.
None Documented
None Documented
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
Terminal elimination half-life: 12–18 hours; clinical context: steady-state reached after 3–5 days of daily dosing
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Renal (80% as metabolites, 20% unchanged); biliary/fecal (minor, <5% total)
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive